Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm - Edgewise Therapeutics ( NASDAQ:EWTX )
Investors can contact the law firm at no cost to learn more about recovering their losses
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 23, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 03, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Aytu BioPharma ( NASDAQ:AYTU ) , Circle Internet Group ( NYSE:CRCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Aytu BioPharma, Inc.
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall - Edgewise Therapeutics ( NASDAQ:EWTX )
99% of eligible Becker participants ( n=85 ) enrolled in MESA showed stable or improved NSAA scores after 18 months. Sevasemten was well tolerated in Phase 2 Duchenne studies; 10 mg dose selected for Phase 3. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news ...
All You Need to Know About Edgewise Therapeutics ( EWTX ) Rating Upgrade to Buy
Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Edgewise Therapeutics ( EWTX ) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Edgewise Therapeutics Stock Popped This Week
On Thursday, an analyst launched coverage of Edgewise Therapeutics ( NASDAQ: EWTX ) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compiled by S&P Global Market Intelligence, its share price vaulted nearly 14% higher across the ...
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , American Assets Trust ( NYSE:AAT )
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 1% on Monday. Shares of Tesla, Inc. TSLA fell sharply in today's pre-market trading following a report indicating the company postponed the US debut of an affordable version of its Model Y SUV.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Edgewise Therapeutics ( NASDAQ:EWTX ) , Camp4 Therapeutics ( NASDAQ:CAMP )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Edgewise Therapeutics ( NASDAQ:EWTX )
100 mg dose led to a 71% mean reduction in resting LVOT gradient and 58% in provokable gradient. NT-proBNP levels dropped 62% in obstructive HCM and 42% in nonobstructive HCM at 100 mg. Feel unsure about the market's next move?
Why Edgewise Therapeutics ( EWTX ) Stock Is Falling - Edgewise Therapeutics ( NASDAQ:EWTX )
Edgewise Therapeutics shares are trading lower by 23.3% during Wednesday's session. The company announced an approximate $200 million offering. The 'Trade of the Day' is now live. Get a high-probability setup with clear entry and exit points right here.
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr ( NASDAQ:CAR ) , Concentrix ( NASDAQ:CNXC )
U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday. Shares of Concentrix Corporation CNXC rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Regenxbio ( NASDAQ:RGNX )
Goldman Sachs downgraded Regenxbio, cutting the price target due to concerns over ABBV-RGX-314's market appeal. Data for ABBV-RGX-314 in wet AMD is expected in 2026, while Phase 3 program for diabetic retinopathy with suprachoroidal delivery is planned
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Aehr Test System ( NASDAQ:AEHR ) , Agios Pharmaceuticals ( NASDAQ:AGIO )
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target from $400 to $515. Tesla shares gained 5% to $458.08 on ...
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Edgewise Therapeutics ( NASDAQ:EWTX )
On Monday, Edgewise Therapeutics, Inc., EWTX revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy ( BMD ) , is a genetic disorder that causes progressive muscle weakness.
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - AtlasClear Holdings ( AMEX:ATCH ) , Akoustis Technologies ( NASDAQ:AKTS )
Shares of Edgewise Therapeutics, Inc. EWTX rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Sevasemten in individuals with becker muscular dystrophy. Edgewise Therapeutics shares jumped 26.5% to $35.00 in the pre-market trading ...
EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing
BB Biotech: Strategic reallocation of portfolio assets progressing Portfolio of BB Biotech AG as at September 30, 2024 A key event during the period under review was the US Federal Reserve's decision in September to lower interest rates by 50 bps, marking its first rate cut in four years.
Analysts Think There's Still Time To Get In On Edgewise - Cytokinetics ( NASDAQ:CYTK ) , Bristol-Myers Squibb ( NYSE:BMY )
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. Yet, with still only a market cap of $2.4 billion, is there still time to get in?
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge - Edgewise Therapeutics ( NASDAQ:EWTX )
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Company News for Sep 20, 2024
Companies In The News Are: PGNY, EWTX, FDS, SCS.
Crude Oil Gains Over 1%; Mobileye Global Shares Jump - Darden Restaurants ( NYSE:DRI )
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 100 500 points on Thursday. The Dow traded up 1.28% to 42,032.26 while the NASDAQ rose 2.65% to 18,038.75. The S&P 500 also rose, gaining, 1.80% to 5,719.64. Information technology shares jumped by 3.3% on ...
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
One of the biopharma company's heart drugs performs as well as initially hoped.
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings - FactSet Research Systems ( NYSE:FDS )
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping more than 500 points on Thursday. The Dow traded up 1.25% to 42,023.61 while the NASDAQ rose 2.30% to 17,976.99. The S&P 500 also rose, gaining, 1.60% to 5,707.97. Information technology shares jumped by 2.9% on ...
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment - Edgewise Therapeutics ( NASDAQ:EWTX )
On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy.
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday - NVIDIA ( NASDAQ:NVDA )
U.S. stocks were higher, with the Dow Jones index surging around 400 points on Thursday. Shares of Darden Restaurants, Inc. DRI rose sharply during Thursday's session following first-quarter results. Darden reported quarterly earnings of $1.75 per share which missed the analyst consensus ...
Here's Why Edgewise Therapeutics, Inc. ( EWTX ) is a Great Momentum Stock to Buy
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Could Biogen Buy? Three Surprise Names That Make Sense.
Biogen ( BIIB ) stock has mostly trended sideways this year, but that could soon change with $8 billion to $10 billion in acquisition-focused dry powder, an analyst said Tuesday. Wedbush analyst Laura Chico notes Biogen wrapped two high-profile acquisitions last year, taking over Reta ...
Biotech Reveals More From The Study That Boosted Shares 83%
Cytokinetics Stock: How Its New Drug Could Be A Safer Version Of Bristol's Camzyos Investor's Business Daily ...
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 - GSK ( NYSE:GSK )
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
Record levels of funding propel Denver-Boulder to the top of the life sciences market
Denver-Boulder is rapidly becoming a life sciences hub thanks to a surge in funding, research collaborations and lab space.
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. ( EWTX ) : Here's What You Should Know
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Insider Favorites: 7 Stocks with Bullish Buying Signals
While investors shouldn't get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it's difficult to tell what insider selling means. After all, investors could exit a position for a number of reasons, including mundane ones ...
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. ( EWTX ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Is The Market Feeling About Edgewise Therapeutics? - Edgewise Therapeutics ( NASDAQ:EWTX )
Edgewise Therapeutics's EWTX short percent of float has fallen 58.78% since its last report. The company recently reported that it has 8.17 million shares sold short, which is 15.01% of all regular shares that are available for trading.
Insiders Buying Edgewise Therapeutics And 2 Other Stocks - Tile Shop Holdings ( NASDAQ:TTSH ) , Edgewise Therapeutics ( NASDAQ:EWTX )
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight
Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts ... PR ...
Wall Street Analysts Think Edgewise Therapeutics, Inc. ( EWTX ) Could Surge 70.76%: Read This Before Placing a Bet
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise ( EWTX ) Rallies 35% on Issue of New Common Stock
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Edgewise Therapeutics Scores Relative Strength Rating Upgrade
Edgewise Therapeutics ( EWTX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, with an upgrade from 88 to 97. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
What's Going On With Edgewise Therapeutics Stock? - Edgewise Therapeutics ( NASDAQ:EWTX )
Edgewise Therapeutics, Inc. EWTX shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday - World Acceptance ( NASDAQ:WRLD )
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation WRLD rose sharply during Friday's session following upbeat quarterly results. World Acceptance posted quarterly earnings of $2.84 per share, beating market estimates of ...
